drugset / Trial / NCT03462342
Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Investigational agent, AZD6738 will be given in combination with Olaparib to women with recurrent ovarian cancer (platinum-sensitive or platinum-resistant). This study will determine if using Olaparib in combination with AZD6738 is safe and tolerable and also determine the objective response rate and progression free survival of combination of AZD6738 and Olaparib in women with recurrent ovarian cancer in distinct platinum-sensitive and platinum-resistant cohorts.
Timeline
- Start
- 2018-03-09
- Primary completion
- 2025-07-21
- Completion
- 2025-07-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ceralasertib | Small molecule | 80 mg | Oral |
| Subject | Ceralasertib | Small molecule | 120 mg | Oral |
| Subject | Ceralasertib | Small molecule | 160 mg | Oral |
| Subject | Ceralasertib | Small molecule | 240 mg | Oral |
| Subject | Ceralasertib | Small molecule | 320 mg | Oral |
| Subject | Olaparib | Small molecule | 100 mg | Oral |
| Subject | Olaparib | Small molecule | 150 mg | Oral |
| Subject | Olaparib | Small molecule | 200 mg | Oral |
| Subject | Olaparib | Small molecule | 300 mg | Oral |